NASDAQ:QGEN - Qiagen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$35.91 +0.46 (+1.30 %)
(As of 10/19/2018 04:00 PM ET)
Previous Close$35.45
Today's Range$35.67 - $36.27
52-Week Range$30.20 - $39.45
Volume1.62 million shs
Average Volume972,723 shs
Market Capitalization$7.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.98
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryLife Sciences Tools & Services
SectorN/A
SymbolNASDAQ:QGEN
CUSIPN7248210
Phone+31-77-3556600

Debt

Debt-to-Equity Ratio0.69
Current Ratio5.07
Quick Ratio4.59

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio26.80
P/E Growth1.93

Sales & Book Value

Annual Sales$1.42 billion
Price / Sales5.78
Cash Flow$2.6541 per share
Price / Cash13.53
Book Value$11.13 per share
Price / Book3.23

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$40.39 million
Net Margins2.85%
Return on Equity11.74%
Return on Assets6.28%

Miscellaneous

Employees4,684
Outstanding Shares228,230,000
Market Cap$7.77 billion

Qiagen (NASDAQ:QGEN) Frequently Asked Questions

What is Qiagen's stock symbol?

Qiagen trades on the NASDAQ under the ticker symbol "QGEN."

How will Qiagen's stock buyback program work?

Qiagen announced that its board has authorized a stock repurchase plan on Thursday, February 1st 2018, which authorizes the company to repurchase $200,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's management believes its stock is undervalued.

How were Qiagen's earnings last quarter?

Qiagen NV (NASDAQ:QGEN) issued its quarterly earnings data on Tuesday, July, 31st. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.32 by $0.01. The firm earned $377.20 million during the quarter, compared to analysts' expectations of $376.89 million. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. View Qiagen's Earnings History.

When is Qiagen's next earnings date?

Qiagen is scheduled to release their next quarterly earnings announcement on Monday, October 29th 2018. View Earnings Estimates for Qiagen.

What guidance has Qiagen issued on next quarter's earnings?

Qiagen updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share guidance of $1.31-1.33 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.34. The company issued revenue guidance of $1.50-1.52 billion (+6-7% CER), compared to the consensus revenue estimate of $1.54 billion.Qiagen also updated its Q3 guidance to $0.33-0.34 EPS.

What price target have analysts set for QGEN?

12 brokerages have issued 1-year price objectives for Qiagen's stock. Their predictions range from $34.00 to $44.00. On average, they expect Qiagen's stock price to reach $38.8750 in the next twelve months. This suggests a possible upside of 8.3% from the stock's current price. View Analyst Price Targets for Qiagen.

What is the consensus analysts' recommendation for Qiagen?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen.

Are investors shorting Qiagen?

Qiagen saw a decrease in short interest in August. As of August 31st, there was short interest totalling 2,998,011 shares, a decrease of 45.8% from the August 15th total of 5,534,173 shares. Based on an average daily trading volume, of 819,805 shares, the short-interest ratio is currently 3.7 days. Approximately 1.4% of the company's stock are short sold. View Qiagen's Current Options Chain.

Who are Qiagen's key executives?

Qiagen's management team includes the folowing people:
  • Manfred E. Karobath, Chairman of the Supervisory Board (Age 76)
  • Peer M. Schatz, Chief Executive Officer, Managing Director
  • Roland Sackers, Chief Financial Officer
  • Thomas Schweins, Senior Vice President - Human Resources, Strategy & Marketing Services
  • Thierry Bernard, Senior Vice President - Molecular Diagnostics Business Area
  • Laura Furmanski, Senior Vice President - Bioinformatics Business Area
  • Douglas Liu, Senior Vice President - Global Operations
  • Manuel O. Mendez, Senior Vice President - Global Commercial Operations
  • Stephane Bancel, Independent Supervisory Director (Age 44)
  • Hakan Bjorklund, Supervisory Board Director (Age 61)

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different of retail and institutional investors. Top institutional investors include Hardman Johnston Global Advisors LLC (1.83%), Manning & Napier Group LLC (0.49%), Bank of Montreal Can (0.36%), Aperio Group LLC (0.09%), Nisa Investment Advisors LLC (0.03%) and Fox Run Management L.L.C. (0.01%).

Which major investors are selling Qiagen stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC and Aperio Group LLC.

Which major investors are buying Qiagen stock?

QGEN stock was bought by a variety of institutional investors in the last quarter, including Hardman Johnston Global Advisors LLC, Bank of Montreal Can, Nisa Investment Advisors LLC, Fox Run Management L.L.C., Seven Eight Capital LP, Oakbrook Investments LLC, State of Alaska Department of Revenue and Lourd Capital LLC.

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $35.91.

How big of a company is Qiagen?

Qiagen has a market capitalization of $7.77 billion and generates $1.42 billion in revenue each year. Qiagen employs 4,684 workers across the globe.

What is Qiagen's official website?

The official website for Qiagen is http://www.qiagen.com.

How can I contact Qiagen?

Qiagen's mailing address is Hulsterweg 82, VENLO, 5912 PL, Netherlands. The company can be reached via phone at +31-77-3556600 or via email at [email protected]


MarketBeat Community Rating for Qiagen (NASDAQ QGEN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  434 (Vote Underperform)
Total Votes:  766
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2018 by MarketBeat.com Staff

Featured Article: Marijuana Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel